Combination chemotherapy of 5-fluorouracil (5-FU) , adriamycin (ADM) , cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer
Ozeki, H.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Mukaiyama, T.; Nagamine, D.; Ito, Y.; Imajo, K.; Shinagawa, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(1): 91-95
1988
ISSN/ISBN: 0385-0684 PMID: 3122669 Document Number: 317030
Twenty patients with advanced gastric cancer were treated with FAP.MMC (5-FU 350 mg/m2 i.v. on days 1-3, ADM 40 mg/m2 i.v. on day 1, CDDP 20 mg/m2 i.v. on days 1-3, MMC 6 mg/m2 i.v. on day 1), administering 5-FU, ADM and CDDP every 4 weeks and MMC every 8 weeks. Fourteen patients were evaluable for responses. Four (29%) partial responses and two minor responses were observed. The median duration of partial response was 3.8 months (range 2.5-7 months). The median overall survival time was 5 months (range 1.5-15 months). Leukopenia was relatively severe, with a median WBC nadir of 1,300/mm3. Nausea and vomiting were frequent but moderate. However, these toxicities were clinically manageable. FAP.MMC was thus considered effective for advanced gastric cancer.